Novavax posts higher-than-expected revenue, says prepared to further cut costs

 COVID-19 vaccine maker Novavax (NVAX.O) on Thursday reported higher-than-expected revenue for the third quarter, boosted by U.S. government grants to help cover the expense of clinical trials, and said it was prepared to further cut costs next year.